Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.75
Bid: 32.50
Ask: 33.00
Change: -0.25 (-0.76%)
Spread: 0.50 (1.538%)
Open: 32.50
High: 32.75
Low: 32.50
Prev. Close: 33.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Apr 2022 07:00

RNS Number : 8761H
Duke Royalty Limited
11 April 2022
 

11 April 2022

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, is pleased to provide the following trading update for its fourth financial quarter ended 31 March 2022 ("Q4 FY22"), and to provide guidance on trading for the first quarter of the Company's 2023 financial year, ending 30 June 2022 ("Q1 FY23").

Financial Highlights:

Q4 FY22 represented a record quarter of cash generation in the Company's five-year operating history, both in terms of total cash revenue* and normalised cash revenue**  Total cash revenue was £6.7 million, representing a 37% increase over the previous record quarterly flows in Q2 FY22 of £4.9 million Normalised cash revenue totalled £4.7 million, an increase of 21% on the previous quarter and an 88% increase over Q4 FY21 Following the Company's £5.3 million follow-on investment into Miriad Products ("Miriad") in December 2021, Miriad completed its shareholder restructure in Q4 FY22, realising £1.9 million of cash proceeds to Duke whilst still retaining its 30% equity stake in the business Duke Royalty's last four quarters of Normalised Cash Revenue and Total Cash Revenue are as follows: 

-

Normalised Cash Revenue**

Total Cash Revenue*

Q1 FY22

£2.9 million

£2.9 million

Q2 FY22

£3.3 million

£4.9 million

Q3 FY22

£3.9 million

£3.9 million

Q4 FY22

£4.7 million

£6.7 million

 

* Total cash revenue is monthly cash distributions from Duke's royalty partners plus cash gains received from the sales of equity assets and redemption premiums

** Normalised cash revenue excludes redemption premium receipts and cash gains from equity sales

 

Based on current trading, Duke expects Q1 FY23 normalised cash revenue to be £5.0 million 

Capital Deployments:

During Q4 FY22, Duke committed a further £13.3m of investment to support the "buy and build" strategies of four of its current royalty partners. This was made up of five separate follow-on transactions as follows: 

 -

Two investments into InTec Business Solutions Limited of £2.45 million in January and £1.65 million in February to finance the acquisitions of Provident Technology Limited, Firefly Enterprises Limited and Opal IT Limited, respectively

 -

A £1.5 million investment into Lynx Equity (UK) Ltd to facilitate their acquisition of Obel-P Automation A/S

 -

A £1.55 million investment into Tristone Healthcare Limited to finance its acquisition of Seaside Care Homes Limited

 -

A CA$10.3 million (£6.2 million) investment into Creō-Tech Industrial Group Inc, facilitating the purchase of California-based MD Stainless Services

 Other Q4 Highlights

A second consecutive quarterly dividend rise, increasing 17% from 0.60 pence per quarter to 0.70 pence Drew down the £20 million accordion facility with Honeycomb Investment Trust, unlocking additional liquidity Cash receipt of €4 million from the early repayment of the 2nd tranche of deferred consideration relating to the sale of Duke's three European river cruise vessels. This amount had originally been due for repayment by 30 September 2022. Currently only €2.6 million remains outstanding and due for repayment on or before 30 June 2023 

Neil Johnson, CEO of Duke Royalty, said:

"It is pleasing to report that normalised cash revenue has continued to grow, with Q4 FY22 representing the sixth consecutive quarterly cash revenue increase since the initial impact of Covid. Given Duke's largely fixed cost base, the recent acceleration in deployments has led to a material increase in cashflow per share and we are delighted to be able to share this operational leverage with our shareholders through increasing the quarterly dividend which has risen 27% in the last year.

"We continue to see a strong pipeline of royalty opportunities to service both existing and new companies. Despite the macroeconomic and geopolitical headwinds, our portfolio as a whole continues to perform well. The resilience demonstrated is a benefit of our exposure to a range of underlying companies across diverse geographies and sectors."

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 730 613

Cenkos Securities plc 
(Nominated Adviser
and Joint Broker)
 
Stephen Keys / Callum Davidson / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

 

 

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell / Richard Bicknell / Max Richardson

 

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLTSIIILIF
Date   Source Headline
5th Aug 20205:43 pmRNSHolding(s) in Company
27th Jul 20202:05 pmRNSSecond Price Monitoring Extn
27th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
3rd Jul 20203:15 pmRNSIssue of Equity for Scrip Dividend
2nd Jul 20207:00 amRNSScrip Dividend Reference Price
18th Jun 20207:00 amRNSFollow-on contribution to royalty partner
17th Jun 20207:01 amRNSDividend Declaration
17th Jun 20207:00 amRNSIssue of Equity
14th May 20202:05 pmRNSSecond Price Monitoring Extn
14th May 20202:00 pmRNSPrice Monitoring Extension
14th May 20207:00 amRNSTrading and Dividend Update
6th May 20204:42 pmRNSSecond Price Monitoring Extn
6th May 20204:36 pmRNSPrice Monitoring Extension
5th May 20204:45 pmRNSHolding(s) in Company
2nd Apr 20207:00 amRNSTrading Update re: COVID-19
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:35 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSFollow-on contribution to royalty partner
11th Mar 20207:01 amRNSDividend Declaration & Trading Update
11th Mar 20207:00 amRNSDirectorate Change
30th Jan 20207:00 amRNSFollow-on contribution to royalty partner
23rd Jan 202012:35 pmRNSHolding(s) in Company
13th Jan 20207:00 amRNSPortfolio Update
9th Jan 20205:23 pmRNSHolding(s) in Company
9th Jan 20205:20 pmRNSHolding(s) in Company
16th Dec 20197:00 amRNSDividend Declaration
6th Dec 20197:01 amRNSLong Term Incentive Plan Awards
6th Dec 20197:00 amRNSInterim Results
4th Nov 20197:00 amRNSPaydown of Revolving Credit Facility
1st Nov 20197:00 amRNSFollow-on contribution to royalty partner
31st Oct 20193:19 pmRNSDirectors' Dealings
30th Oct 20191:55 pmRNSResult of EGM and Issue of £17.5 million of Equity
25th Oct 20197:00 amRNSNotification of major holdings
16th Oct 201911:26 amRNSResult of Annual General Meeting
7th Oct 20197:00 amRNSResult of Retail Offer and Open Offer Details
4th Oct 20194:31 pmRNSRetail Offer via PrimaryBid.com
4th Oct 20194:30 pmRNSFundraising of up to £20 million
19th Sep 20197:00 amRNSIncreased Interim Dividend & Dividend Declaration
18th Sep 20197:00 amRNSPosting of Report & Accounts and Notice of AGM
10th Sep 20197:00 amRNSIncreased £30M Credit Facility on Improved Terms
9th Sep 20197:00 amRNSFiscal 2019 Final Results
29th Aug 20197:00 amRNSFollow-On Contribution and Restructuring
14th Aug 20197:00 amRNSUpdate and Notice of Results
25th Jul 20195:51 pmRNSNotification of major holdings
19th Jun 20197:00 amRNSDividend Declaration
28th May 20197:00 amRNSFollow-on contribution to royalty partner
14th May 20191:00 pmRNSModification of Partners' Agreements - Amendment
14th May 20197:00 amRNSModification of Partners' Agreements
7th May 20197:00 amRNSNotification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.